3月27日,迈博药业(02181)发布截至2024年12月31日的年度业绩公告。报告期内,公司的营业收入为2.58亿元,较2023年同期的8716万元增长196.3%。具体财务摘要如下图:公司在管理层讨论与分析部分提到,CMAB009的上市以及CMAB007和CMAB008的稳固销售增长是营业收入大幅增长的主要原因。此外,CMAB007的销售额同比大幅增加。尽管研发开支有所减少,行政开支却略有上升...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.